Company news
Avalo Therapeutics, Inc. (NASDAQ:AVTX) news
Every Avalo Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
August 6, 2026
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
July 22, 2026
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
July 7, 2026
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
June 26, 2026
Avalo Therapeutics Appoints Ron Philip to Board of Directors
June 23, 2026
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
June 16, 2026
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 13, 2026
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
May 5, 2026
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 5, 2026
Avalo Therapeutics Purchases Optional Milestone Buyout
April 28, 2026
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
March 23, 2026
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 4, 2026
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
November 17, 2025
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
November 6, 2025
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 29, 2025
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
October 1, 2025
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
September 22, 2025
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
August 7, 2025
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
June 18, 2025
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
May 12, 2025
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
April 30, 2025
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
March 26, 2025
Avalo Reports 2024 Financial Results and Recent Business Updates
March 20, 2025
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
January 2, 2025
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
November 12, 2024
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
November 7, 2024
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 8, 2024
Avalo Announces Participation in September Investor Conferences
September 4, 2024
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 9, 2024
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
June 24, 2024
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 2, 2024
Avalo Reports 2023 Financial Results and Provides Business Updates
March 29, 2024
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
December 27, 2023
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
December 7, 2023
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 9, 2023
Avalo Completes Divestiture of AVTX-800 Series
October 31, 2023
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
September 26, 2023
Avalo Enters into Agreement to Divest AVTX-800 Series
September 12, 2023
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 6, 2023
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 3, 2023
Avalo to Participate in SVB Securities Therapeutics Forum
July 6, 2023
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
June 26, 2023
Avalo to Present at the Jefferies Healthcare Conference
June 1, 2023
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 22, 2023